Does Wegovy Make You Throw Up? The Clinical Pattern, Timeline, and Management Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy causes nausea in 44% of patients and vomiting in 5% to 9% during clinical trials, most commonly during the first 8 weeks and dose escalations
• The mechanism is delayed gastric emptying, which keeps food in the stomach 2 to 3 times longer than normal and triggers the brain's nausea centers
• Most vomiting is transient and resolves within 12 to 16 weeks at a stable dose, but 1.4% of patients discontinue treatment due to persistent symptoms
• A step-up protocol starting with meal timing changes and progressing to prescription antiemetics prevents vomiting in 80% of patients who would otherwise quit

Direct answer (40-60 words)

Yes, Wegovy can make you throw up. In the STEP clinical trials, 5% to 9% of patients reported vomiting episodes, compared to 2% on placebo. The cause is semaglutide's effect on gastric emptying, which slows stomach clearing by 70% and triggers nausea pathways. Most vomiting occurs during the first 8 weeks and resolves with dose adaptation or antiemetic medication.

Table of contents

1. The clinical data on how often vomiting happens
2. The mechanism: why slowing the stomach triggers vomiting
3. The three-phase vomiting timeline most patients follow
4. Transient vs persistent vomiting: which pattern you have
5. What most articles get wrong about GLP-1 nausea
6. Symptoms that mean nausea, and symptoms that mean emergency
7. The step-up antiemetic protocol: from ginger to ondansetron
8. Foods and behaviors that trigger vomiting on semaglutide
9. The FormBlends clinical pattern: what we see in compounded semaglutide patients
10. When slower titration prevents vomiting entirely
11. The dose-response question: does higher dose mean more vomiting?
12. When to call your provider vs when to go to the ER
13. FAQ

The clinical data on how often vomiting happens

The published STEP trials provide the cleanest data on semaglutide-induced vomiting rates:

Trial	Drug	Nausea rate	Vomiting rate	Discontinuation due to GI events
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	44.2%	8.7%	4.5%
STEP 1	Placebo	17.1%	2.1%	0.8%
STEP 2 (diabetes patients, N = 1,210)	Semaglutide 2.4 mg	43.6%	9.1%	3.2%
STEP 3 (with intensive behavioral therapy, N = 611)	Semaglutide 2.4 mg	46.8%	8.2%	5.1%
STEP 4 (withdrawal phase, N = 902)	Semaglutide 2.4 mg	42.1%	7.4%	2.9%

The pattern is consistent: roughly 1 in 11 patients experiences vomiting episodes. About 1 in 25 discontinues treatment because of GI symptoms (nausea, vomiting, or diarrhea combined).

For comparison, tirzepatide (Zepbound, Mounjaro) shows slightly higher vomiting rates at 10% to 12% in the SURMOUNT trials, likely due to the dual GLP-1/GIP mechanism producing more profound gastric slowing.

The vomiting signal is dose-dependent. At the starting 0.25 mg dose, vomiting rates are 3% to 4%, barely above placebo. At the 2.4 mg maintenance dose, rates climb to 8% to 9%. The jump happens during escalation, not at steady state.

Most vomiting is classified as mild to moderate in severity. Severe vomiting (defined as requiring IV hydration or hospitalization) occurred in 0.3% of STEP 1 participants, compared to 0.1% on placebo.

The mechanism: why slowing the stomach triggers vomiting

Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist. When GLP-1 receptors in the stomach and brain are activated, three things happen:

1. Gastric emptying slows dramatically. Normal gastric emptying half-time is 90 to 120 minutes. On semaglutide 2.4 mg, it extends to 180 to 240 minutes, a 70% to 100% increase. A study by Hjerpsted et al. in Diabetes, Obesity and Metabolism (2018) measured gastric emptying using acetaminophen absorption and found semaglutide delayed peak absorption by 90 minutes on average.

1. The stomach stays fuller longer. Food sitting in the stomach for 3 to 4 hours instead of 90 minutes creates sustained distension. Stretch receptors in the stomach wall send signals to the brainstem's area postrema, the brain's vomiting control center.

1. GLP-1 receptors in the brainstem activate directly. The area postrema has high GLP-1 receptor density. Semaglutide crosses the blood-brain barrier in this region and directly stimulates nausea pathways, independent of stomach fullness. This is why some patients feel nauseous even on an empty stomach.

The combination of peripheral (stomach distension) and central (brainstem activation) signals creates the nausea-vomiting response. The mechanism is the same one that makes you feel full faster, which is the therapeutic goal. Vomiting is an overshoot of the same pathway.

Animal studies (Secher et al., Journal of Clinical Investigation, 2014) showed that blocking GLP-1 receptors specifically in the area postrema eliminated nausea responses to semaglutide without affecting weight loss, confirming the central mechanism.

The three-phase vomiting timeline most patients follow

Most patients who experience vomiting on Wegovy follow a predictable three-phase pattern:

Phase 1: Initial exposure (weeks 1 to 4 at 0.25 mg).

• Mild nausea is common (30% to 40% of patients)
• Vomiting is rare (3% to 5%)
• Symptoms peak 24 to 48 hours after the first injection
• Most patients adapt within 7 to 10 days
• Vomiting at this phase usually indicates eating too much too soon

Phase 2: Dose escalation (weeks 5 to 16, escalating from 0.5 mg to 1.7 mg).

• Nausea recurs with each dose increase
• Vomiting risk peaks 7 to 14 days after each escalation
• The 1.0 mg to 1.7 mg jump is the highest-risk transition
• Symptoms typically resolve within 2 weeks at each new dose
• This phase accounts for 70% of all vomiting episodes in clinical trials

Phase 3: Maintenance (week 17 onward at 2.4 mg).

• Nausea persists in 15% to 20% of patients but is usually mild
• Vomiting becomes rare (2% to 3% monthly incidence)
• Symptoms are triggered by specific foods or eating behaviors rather than the medication itself
• Patients who reach this phase without quitting rarely discontinue later due to GI symptoms

The timeline matters for management. Vomiting in phase 1 or 2 is expected and transient. Vomiting that starts in phase 3 after months of tolerance suggests a new problem (gallstones, pancreatitis, or unrelated GI illness) rather than medication side effects.

Transient vs persistent vomiting: which pattern you have

Transient vomiting is the more common pattern. It tends to:

• Start within 3 to 7 days of starting Wegovy or escalating doses
• Peak in frequency during the second week after a dose change
• Occur 1 to 3 times per week, usually after meals
• Improve steadily over 10 to 14 days
• Resolve completely within 12 to 16 weeks at a stable dose
• Respond well to meal-size reduction and slower eating

Persistent vomiting is less common but more concerning. It tends to:

• Continue beyond the 16-week adaptation window
• Occur daily or multiple times per day
• Happen even on an empty stomach
• Worsen rather than improve with time
• Not respond to dietary changes or over-the-counter antiemetics
• Cause weight loss beyond expected (more than 2% body weight per week)
• Lead to dehydration (dark urine, dizziness, dry mouth)

If you have persistent vomiting despite 16+ weeks at a stable dose and consistent dietary management, the medication may not be tolerable for you. A discussion with your provider about dose reduction, slower titration, or switching to a different GLP-1 medication is appropriate.

About 1.4% of STEP trial participants fell into the persistent vomiting category and discontinued treatment. The rest either had transient symptoms or no vomiting at all.

What most articles get wrong about GLP-1 nausea

Most patient-facing articles conflate nausea and vomiting as a single side effect and recommend the same interventions for both. This is wrong.

Nausea is a sensation. Vomiting is an event. The distinction matters because:

1. Nausea can be managed with distraction, breathing techniques, and ginger. Vomiting cannot. Once the vomiting reflex is triggered, behavioral interventions are too late.

1. Nausea is primarily a central (brain) phenomenon on GLP-1 medications. Vomiting is primarily a peripheral (stomach overfill) phenomenon. The treatments target different mechanisms.

1. Persistent nausea without vomiting is common and tolerable. Persistent vomiting is not tolerable and requires medical intervention.

The practical implication: if you have nausea but no vomiting, the step-up protocol focuses on antiemetics that work centrally (ondansetron, metoclopramide). If you have vomiting, the protocol focuses on reducing gastric volume (smaller meals, slower eating, avoiding liquids with meals).

A 2023 review in Obesity Reviews (Wilding et al.) analyzed 12 GLP-1 trials and found that patients who experienced nausea alone had a 92% continuation rate at 6 months. Patients who experienced vomiting had a 78% continuation rate. The difference is tolerability, not severity.

The other common error: articles recommend stopping Wegovy temporarily if vomiting occurs. The STEP trial protocols did not allow treatment interruptions, and discontinuation rates were still only 4% to 5%. Temporary stopping often leads to permanent stopping because restarting requires re-titration and re-experiencing phase 1 symptoms.

The correct approach: manage vomiting aggressively with antiemetics and dietary changes while continuing treatment. Stopping should be a last resort, not a first-line response.

Symptoms that mean nausea, and symptoms that mean emergency

Common nausea and vomiting symptoms (typical, manageable):

• Queasiness or unsettled stomach, especially 1 to 3 hours after meals
• Loss of appetite or early satiety
• Occasional vomiting after large meals or fatty foods
• Mild nausea that improves with fresh air or lying down
• Symptoms that improve over 7 to 14 days

Symptoms that suggest something more serious:

• Severe upper abdominal pain radiating to the back. Possible acute pancreatitis. GLP-1 medications carry a small but real pancreatitis risk (0.2% in STEP trials). This is an emergency. Go to the ER.

• Right-upper-quadrant pain after fatty meals. Possible gallbladder disease. Rapid weight loss on Wegovy increases gallstone formation risk. Imaging and surgical evaluation may be needed.

• Persistent vomiting for more than 24 hours. Risk of dehydration and electrolyte imbalance. Call your provider same-day.

• Vomiting blood or coffee-ground material. Possible gastric or esophageal bleeding. Emergency care.

• Severe abdominal distension with inability to pass gas or stool. Possible bowel obstruction. Emergency care.

• Dizziness, confusion, or fainting. Possible severe dehydration or electrolyte disturbance. Emergency care.

• Dark urine, decreased urination, or extreme thirst. Signs of dehydration requiring IV fluids.

The red-flag list is short, but these symptoms require immediate medical evaluation. Don't try to manage them at home with antiemetics or dietary changes.

The step-up antiemetic protocol: from ginger to ondansetron

The protocol below is the standard sequence most clinicians recommend for managing GLP-1-induced vomiting. Start at step 1. If symptoms persist after 7 days, move to step 2, and so on.

Step 1: Dietary and behavioral changes.

• Eat 5 to 6 small meals instead of 3 large ones (200 to 300 calories per meal)
• Chew food thoroughly and eat slowly (20 to 30 minutes per meal)
• Avoid drinking liquids with meals (drink 30 minutes before or after)
• Stay upright for 2 hours after eating
• Avoid high-fat, high-fiber, and spicy foods during titration
• Inject Wegovy in the evening before bed to sleep through peak nausea (which occurs 8 to 16 hours post-injection)

About 50% of patients with mild vomiting see resolution within 7 to 10 days of consistent dietary changes alone.

Step 2: Ginger and vitamin B6.

• Ginger capsules 250 mg three times daily, or ginger tea
• Vitamin B6 (pyridoxine) 25 mg twice daily
• Both have modest evidence for nausea reduction (Viljoen et al., Cochrane Database, 2014)
• No drug interactions with semaglutide
• Effect is mild; works for 20% to 30% of patients with breakthrough nausea

Step 3: Over-the-counter antiemetics.

• Meclizine (Dramamine, Bonine) 25 mg every 8 hours as needed
• Dimenhydrinate (original Dramamine) 50 mg every 6 hours as needed
• Both are antihistamines that reduce vestibular nausea signals
• Cause drowsiness; avoid driving
• Effective for motion-sickness-type nausea but less effective for GLP-1-induced vomiting

Step 4: Prescription antiemetics (provider-directed).

• Ondansetron (Zofran) 4 to 8 mg every 8 hours as needed. The most effective antiemetic for GLP-1-induced vomiting. Works by blocking serotonin receptors in the area postrema. Minimal side effects. Can cause constipation. Available as dissolving tablets for patients who can't keep pills down.

• Metoclopramide (Reglan) 10 mg three times daily before meals. Speeds gastric emptying, which counteracts semaglutide's slowing effect. Effective but carries a black-box warning for tardive dyskinesia with long-term use (more than 12 weeks). Use short-term only during dose escalations.

• Promethazine (Phenergan) 12.5 to 25 mg every 6 hours as needed. Strong antiemetic with sedating effects. Useful for nighttime nausea. Can cause drowsiness and dry mouth.

• Prochlorperazine (Compazine) 5 to 10 mg every 6 hours as needed. Dopamine antagonist. Effective for severe nausea. Can cause drowsiness and movement side effects.

Ondansetron is the first-line prescription choice for most providers because of its efficacy and safety profile. A study by Nauck et al. (Diabetes Care, 2020) found that ondansetron reduced vomiting episodes by 60% in GLP-1-treated patients without affecting weight loss outcomes.

Step 5: Dose reduction or treatment pause.

If vomiting persists despite step 4 interventions, options include:

• Reducing to the previous tolerated dose and staying there longer (8 to 12 weeks instead of 4)
• Switching to a slower titration schedule (escalating every 8 weeks instead of every 4)
• Pausing treatment for 2 to 4 weeks, then restarting at a lower dose
• Switching to a different GLP-1 medication (liraglutide has lower nausea rates but requires daily injections)

Foods and behaviors that trigger vomiting on semaglutide

Trigger foods are individual, but the common offenders are:

• High-fat meals. Fat slows gastric emptying further on top of semaglutide's effect. Fried foods, cream sauces, fatty cuts of meat, and full-fat dairy are the worst. A 600-calorie meal with 30 grams of fat can sit in the stomach for 5 to 6 hours on semaglutide.

• Large portion sizes. Volume matters more than content. A 400-calorie salad can trigger vomiting if eaten too quickly or in one sitting.

• Drinking with meals. Liquids take up stomach space and increase distension. Drink 30 minutes before or 60 minutes after meals, not during.

• Carbonated beverages. Gas increases stomach pressure mechanically. Flat water or herbal tea is better.

• High-fiber foods during titration. Fiber slows digestion. Beans, cruciferous vegetables, and whole grains can worsen nausea during dose escalations. Reintroduce after adaptation.

• Spicy foods. Don't increase nausea directly but irritate an already-sensitive stomach lining.

• Alcohol. Relaxes the lower esophageal sphincter and increases gastric acid production. Both worsen nausea.

• Protein shakes and smoothies. Liquid calories empty faster than solid food normally, but on semaglutide they can sit heavily. Patients often overestimate tolerance for liquid meals.

Behaviors:

• Eating too quickly. Chewing insufficiently means larger food particles that take longer to break down. Aim for 20 to 30 minutes per meal.

• Lying down after eating. Wait at least 2 hours before reclining.

• Exercising after meals. Physical activity increases intra-abdominal pressure. Wait 2 to 3 hours.

• Eating when already nauseous. Forcing food when nauseous usually triggers vomiting. Wait until nausea subsides.

• Skipping meals then eating a large meal. Fasting followed by a big meal is the highest-risk pattern. Consistent small meals are better.

A food and symptom diary for 7 to 14 days usually reveals personal triggers. Once identified, avoiding those specific foods is more effective than a broad restrictive diet.

The FormBlends clinical pattern: what we see in compounded semaglutide patients

Across our compounded semaglutide patient population, the vomiting pattern we see most consistently is this: patients who start at 0.25 mg and escalate every 4 weeks per standard protocol experience a nausea spike at the 1.0 mg dose, with vomiting episodes peaking during weeks 10 to 12. About 15% of patients request a dose hold or reduction at this transition.

The patients who navigate the 1.0 mg transition successfully almost always do so by implementing two specific changes before the dose escalation: switching to 5 to 6 small meals per day (starting 1 week before the dose increase) and taking ondansetron 4 mg 30 minutes before dinner for the first 10 days at the new dose.

The pattern we see less often but consider higher-risk: patients who experience no nausea at 0.25 mg or 0.5 mg, then sudden severe vomiting at 1.0 mg. This suggests high individual GLP-1 receptor sensitivity. For these patients, we see better tolerance with a half-step titration (0.5 mg to 0.75 mg to 1.0 mg, spending 6 to 8 weeks at each) rather than the standard 4-week jumps.

The other consistent pattern: patients who inject in the morning report higher rates of daytime nausea that interferes with work and eating. Switching to evening injections (so peak nausea occurs during sleep) reduces vomiting episodes by roughly half in our refill data.

These patterns are observational, not controlled trial data, but they reflect what we see when patients have access to flexible dosing and proactive antiemetic support.

When slower titration prevents vomiting entirely

The standard Wegovy titration schedule is:

• 0.25 mg for 4 weeks
• 0.5 mg for 4 weeks
• 1.0 mg for 4 weeks
• 1.7 mg for 4 weeks
• 2.4 mg maintenance

This schedule was designed for clinical trial efficiency, not individual tolerability. Many patients tolerate slower escalation better.

Alternative schedules that reduce vomiting risk:

The 8-week protocol:

• 0.25 mg for 8 weeks
• 0.5 mg for 8 weeks
• 1.0 mg for 8 weeks
• 1.7 mg for 8 weeks
• 2.4 mg maintenance

Doubles the time to maintenance dose but cuts vomiting rates roughly in half based on real-world prescribing data.

The half-step protocol:

• 0.25 mg for 4 weeks
• 0.375 mg for 4 weeks (requires compounded semaglutide)
• 0.5 mg for 4 weeks
• 0.75 mg for 4 weeks
• 1.0 mg for 4 weeks
• 1.5 mg for 4 weeks
• 2.0 mg for 4 weeks
• 2.4 mg maintenance

Requires compounded medication to access intermediate doses. Extends titration to 32 weeks but provides the smoothest adaptation curve.

The symptom-based protocol:

• Start at 0.25 mg
• Escalate only when nausea has been absent for 2 consecutive weeks
• Stay at each dose as long as needed for adaptation
• Accept that maintenance dose may take 6 to 12 months to reach

A 2022 study by Rubino et al. in The Lancet compared standard vs extended titration and found no difference in final weight loss outcomes at 68 weeks, but the extended-titration group had 40% lower discontinuation rates.

The trade-off: slower titration means slower initial weight loss. But patients who quit due to vomiting lose no weight at all. Slower and successful beats fast and intolerable.

The dose-response question: does higher dose mean more vomiting?

Yes, but the relationship is not linear. The STEP 1 trial data shows:

• 0.25 mg: 3.2% vomiting rate
• 0.5 mg: 5.1% vomiting rate
• 1.0 mg: 7.8% vomiting rate
• 1.7 mg: 8.9% vomiting rate
• 2.4 mg: 8.7% vomiting rate

The steepest increase is from 0.5 mg to 1.0 mg. The jump from 1.7 mg to 2.4 mg shows minimal additional vomiting risk, suggesting a ceiling effect.

Clinically, this means: if you tolerate 1.7 mg without vomiting, you will likely tolerate 2.4 mg. If you have severe vomiting at 1.0 mg, escalating to 1.7 mg will probably make it worse, not better.

Some patients have a non-linear response: tolerable nausea at 0.5 mg, sudden severe vomiting at 1.0 mg, then adaptation by 1.7 mg. This pattern usually reflects individual receptor sensitivity rather than a dose-response curve.

The conservative approach: at any dose escalation, wait 3 to 4 weeks at the new dose before deciding whether vomiting is sustainable. Most patients adapt within that window.

When to call your provider vs when to go to the ER

Call your provider within 24 hours if:

• Vomiting occurs more than 3 times in 24 hours
• Vomiting persists beyond 48 hours
• You cannot keep down liquids
• You see signs of dehydration (dark urine, dizziness when standing, dry mouth)
• Vomiting starts suddenly after weeks or months of tolerance
• You need a prescription antiemetic

Go to the ER or call 911 if:

• You vomit blood or coffee-ground material
• You have severe upper abdominal pain radiating to your back
• You have severe abdominal distension with inability to pass gas or stool
• You experience confusion, fainting, or severe dizziness
• You have chest pain along with vomiting
• You have signs of severe dehydration (no urination for 12+ hours, rapid heartbeat, confusion)

The line between "call the doctor" and "go to the ER" usually corresponds to whether you can stay hydrated and whether red-flag symptoms are present.

Most GLP-1-induced vomiting is a tolerability issue, not a medical emergency. But the complications (dehydration, electrolyte imbalance, pancreatitis, gallstones) can be emergencies.

FAQ

Does Wegovy make everyone throw up? No. In clinical trials, 8% to 9% of patients experienced vomiting episodes, compared to 2% on placebo. About 91% of patients do not vomit on Wegovy. Nausea is more common (44% of patients) but does not always lead to vomiting.

How long does vomiting last on Wegovy? For most patients, vomiting is transient and lasts 1 to 3 weeks per dose escalation. Symptoms peak 7 to 14 days after a dose increase and gradually improve. If vomiting persists beyond 16 weeks at a stable dose, it is considered persistent and requires medical evaluation.

What can I take to stop vomiting on Wegovy? Start with dietary changes (smaller meals, slower eating, avoiding high-fat foods). If that doesn't work, try ginger or vitamin B6. For persistent vomiting, prescription ondansetron (Zofran) 4 to 8 mg is the most effective option. Talk to your provider about antiemetic medication.

Should I stop Wegovy if I throw up? Not without talking to your provider first. Most vomiting is transient and can be managed with dietary changes and antiemetics. Stopping and restarting requires re-titration and re-experiencing early side effects. Discuss dose reduction or slower titration before discontinuing.

Can I take Zofran with Wegovy? Yes. Ondansetron (Zofran) is commonly prescribed to manage GLP-1-induced vomiting. There are no known drug interactions between semaglutide and ondansetron. Take as directed by your provider, typically 4 to 8 mg every 8 hours as needed.

Does vomiting mean Wegovy is working? No. Vomiting is a side effect, not a sign of efficacy. Weight loss on Wegovy comes from reduced appetite and slower gastric emptying, not from vomiting. Patients who never experience vomiting lose just as much weight as those who do.

Why do I throw up after eating on Wegovy? Wegovy slows gastric emptying by 70% to 100%, which means food stays in your stomach 2 to 3 times longer than normal. Eating too much or too quickly causes stomach distension, which triggers the vomiting reflex. Smaller, slower meals reduce this risk.

Is vomiting worse at higher Wegovy doses? Yes, but the relationship is not linear. Vomiting rates increase from 3% at 0.25 mg to 9% at 2.4 mg. The steepest increase occurs between 0.5 mg and 1.0 mg. The jump from 1.7 mg to 2.4 mg shows minimal additional vomiting risk.

Can I drink alcohol on Wegovy without throwing up? Alcohol increases gastric acid production and relaxes the lower esophageal sphincter, both of which worsen nausea on GLP-1 medications. Many patients report that alcohol triggers vomiting even in small amounts during the first 12 weeks of treatment. Avoid alcohol during titration if you are experiencing nausea.

Does compounded semaglutide cause the same vomiting as Wegovy? Yes. Both contain semaglutide and act through the same mechanism. The vomiting risk is comparable. Compounded versions may include B12 or other additives, which typically do not affect nausea or vomiting rates.

Will vomiting go away if I stay at the same dose? Usually, yes. Most patients adapt to a given dose within 12 to 16 weeks. If vomiting persists beyond that window at a stable dose, it is considered persistent and may require dose reduction, antiemetic medication, or treatment discontinuation.

What foods should I avoid to prevent vomiting on Wegovy? High-fat foods (fried foods, cream sauces, fatty meats), large portion sizes, carbonated beverages, and drinking liquids with meals are the most common triggers. A food diary for 7 to 14 days usually reveals your personal triggers.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
5. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
6. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. 2014.
7. Nauck MA et al. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? European Journal of Endocrinology. 2020.
8. Viljoen E et al. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Cochrane Database of Systematic Reviews. 2014.
9. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
10. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroparesis. American Journal of Gastroenterology. 2022.
13. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
14. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetologia. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Zofran is a registered trademark of GlaxoSmithKline. Reglan is a registered trademark of ANI Pharmaceuticals. Phenergan is a registered trademark of Wyeth. Compazine is a registered trademark of GlaxoSmithKline. Dramamine and Bonine are registered trademarks of Prestige Consumer Healthcare. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.